SomaLogic Proteomics Reveals New Biomarkers in NASH
Key Findings from Clinical Trial
Non-alcoholic Fatty Liver Disease (NAFLD) and Non-alcoholic Steatohepatitis (NASH) are metabolic diseases with no approved therapies. We conducted a Phase 2a trial (NCT03248882) with Clesacostat (PF-05221304), an acetyl coA carboxylase inhibitor (ACCi), in patients with NAFLD/NASH.
Our SomaLogic serum proteome profiling identified potential biomarkers associated with baseline clinical measures of NAFLD/NASH and biomarkers of treatment response to ACCi. The study revealed a set of 69 analytes that robustly correlate with clinical measures of hepatic inflammation and steatosis, 27 of which were significantly reversed with ACC inhibition.
Our data demonstrate the utility of SomaLogic- analyte panel for diagnosis and treatment response in NAFLD/NASH and provide potential new mechanistic insights into liver steatosis reduction, inflammation, and serum triglyceride elevation with ACC inhibition.
Practical Solutions and Value
Enhancing Clinical Practice with DocSym
DocSym, our AI-driven platform, consolidates ICD-11 standards, clinical protocols, and research into a single, easily accessible knowledge base for clinicians, extending the benefits of clinical trials into everyday medical practice.
Streamlining Healthcare Operations with Mobile Apps
Our mobile apps support scheduling, monitoring treatments, and telemedicine, making it easier to manage patient care and expand services digitally, enhancing workflows and improving patient outcomes while reducing paper routine.
Learn more about how we can help at aidevmd.com.
